financetom
Business
financetom
/
Business
/
BRIEF-Couche-Tard Chairman - We Would Not Participate In A Potential IPO Of The US Business
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Couche-Tard Chairman - We Would Not Participate In A Potential IPO Of The US Business
Mar 12, 2025 8:19 PM

March 13 (Reuters) - Alimentation Couche-Tard ( ANCTF )

* CHAIRMAN: WE HAVE HAD MANY DISCUSSIONS WITH SEVEN & I'S

DACUS

BUT IT HAS ALWAYS STOPPED AT THE REGULATORY ASK, THE THING THAT

WE CANNOT OVERCOME

* CEO: WE ARE ENCOURAGED BY THE INTEREST IN OUR DIVESTMENT

PACKAGE

THAT HAS GONE TO MARKET

* CHAIRMAN: WE COULD UNLOCK MORE VALUE BY DEEPENING OUT

UNDERSTANDING THROUGH DUE DILIGENCE BUT WE HAVE VIRTUALLY NO

ACCESS TO INFORMATION NOW

* CEO: WE SEE LOTS OF AREAS OF COOPERATION WITH SEVEN & I

INCLUDING MERCHANDISING, SUPPLY CHAIN, FOOD OFFERINGS,

DIGITALISATION AND CUSTOMER ENGAGEMENT

* CEO: WE SENT OUT A TEAM TO THE TOHOKU REGION AND WE SAW

THAT WE

DO THE SAME THING IN DISASTER RESPONSE SITUATIONS

* CFO: I THINK INVESTOR UNCERTAINTIES AROUND THE MANAGEMENT

PLAN

ARE REFLECTED IN SEVEN & I'S SHARE PRICE

* CEO: WE ARE CONSIDERING VARIOUS ALTERNATIVE STRUCTURES AND

CARVING OUT THE JAPANESE BUSINESS IS ONE POSSIBILITY

* CHAIRMAN: BUT WE WOULD KEEP CONTROL

* CHAIRMAN: WE WOULD NOT PARTICIPATE IN A POTENTIAL IPO OF

THE US

BUSINESS

* CEO: WE BELIEVE THERE WILL BE SIGNIFICANT INTEREST IN THE

DIVESTITURE PACKAGE

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Allogene Therapeutics Q1 Loss Narrows, Revenue Declines
Allogene Therapeutics Q1 Loss Narrows, Revenue Declines
May 13, 2024
04:14 PM EDT, 05/13/2024 (MT Newswires) -- Allogene Therapeutics ( ALLO ) reported Q1 net loss Monday of $0.38 per diluted share, narrowing from $0.69 a year ago. Analysts polled by Capital IQ expected a loss of $0.41. Collaboration revenue for the quarter ended March 31 was $22,000, down from $30,000 a year earlier. Analysts surveyed by Capital IQ expected...
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing
May 13, 2024
04:14 PM EDT, 05/13/2024 (MT Newswires) -- Jean Jacques Bienaime, Director, on May 09, 2024, sold 40,000 shares in Biomarin Pharmaceutical ( BMRN ) for $3,255,200. Following the Form 4 filing with the SEC, Bienaime has control over a total of 722,527 shares of the company, with 474,994 shares held directly and 247,533 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000079/xslF345X03/wk-form4_1715630235.xml ...
Spar Group Insider Sold Shares Worth $1,800,000, According to a Recent SEC Filing
Spar Group Insider Sold Shares Worth $1,800,000, According to a Recent SEC Filing
May 13, 2024
04:15 PM EDT, 05/13/2024 (MT Newswires) -- Williams H Bartels, 10% Owner, Director, on May 09, 2024, sold 1,000,000 shares in Spar Group (SGRP) for $1,800,000. Following the Form 4 filing with the SEC, Bartels has control over a total of 4,709,837 shares of the company, with 4,709,837 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1004989/000143774924016221/xslF345X03/rdgdoc.xml ...
American Express Insider Sold Shares Worth $3,578,087, According to a Recent SEC Filing
American Express Insider Sold Shares Worth $3,578,087, According to a Recent SEC Filing
May 13, 2024
04:19 PM EDT, 05/13/2024 (MT Newswires) -- Jennifer Skyler, Chief Corporate Affairs Officer, on May 10, 2024, sold 14,802 shares in American Express ( AXP ) for $3,578,087. Following the Form 4 filing with the SEC, Skyler has control over a total of 16,371 shares of the company, with 16,371 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/4962/000112760224015075/xslF345X03/form4.xml Price: 238.65, Change: -0.01,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved